Boston Scientific’s Wingspan Intracranial Stent Gets Humanitarian Exemption
This article was originally published in The Gray Sheet
Executive Summary
Boston Scientific will continue efforts to earn Medicare coverage for the Wingspan intracranial stent after announcing HDE approval of the device Aug. 9
You may also be interested in...
FDA Narrows Indication For Stryker’s Wingspan Intracranial Stent
Agency restricts use of the device to a select patient population with severe intracranial stenosis and recurrent stroke after reviewing studies indicating the device could actually lead to increased rates of stroke and death.
Neuro Panel: Wingspan Stent’s Probable Benefits No Longer Outweigh Risks
Recent post-market study data leads FDA’s Neurological Devices panel to conclude that the intracranial stent system, which gained humanitarian device exemption approval in 2005, no longer shows probable benefits outweighing the risks.
Regulatory News In Brief
Group urges FDA to pull Stryker’s Wingspan stent from the market, among other regulatory updates.